In recent years, targeted therapy of ErbB2 has become a research hotspot in breast cancer treatment, and the upregulation of ErbB2 receptor was closely related to the occurrence of breast cancer (Xu et al., 2019). Here, ERBB2 is linked to breast carcinoma.